Zentalis Pharmaceuticals Inc [ZNTL] stock is trading at $1.28, up 2.40%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ZNTL shares have gain 5.79% over the last week, with a monthly amount drifted -5.88%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] stock has seen the most recent analyst activity on August 12, 2024, when Wedbush upgraded its rating to a Neutral but kept the price target unchanged to $4 for it. Previously, UBS downgraded its rating to Neutral on June 20, 2024, and dropped its price target to $5. On June 18, 2024, downgrade downgraded it’s rating to Equal Weight. Wedbush downgraded its rating to a Underperform and decreased its price target to $4 on June 18, 2024. Morgan Stanley downgraded its rating to a Equal-Weight and reduced its price target to $8 on June 18, 2024. Jefferies downgraded its rating to Hold for this stock on June 18, 2024, and downed its price target to $6. In a note dated November 08, 2023, Wedbush downgraded an Neutral rating on this stock and revised its target price from $38 to $12.
Zentalis Pharmaceuticals Inc [ZNTL] stock has fluctuated between $1.01 and $13.00 over the past year. Currently, Wall Street analysts expect the stock to reach $21.86 within the next 12 months. Zentalis Pharmaceuticals Inc [NASDAQ: ZNTL] shares were valued at $1.28 at the most recent close of the market. An investor can expect a potential return of 1607.81% based on the average ZNTL price forecast.
Analyzing the ZNTL fundamentals
Zentalis Pharmaceuticals Inc [NASDAQ:ZNTL] reported sales of 26.86M for the trailing twelve months, which represents a drop of -100.00%. Gross Profit Margin for this corporation currently stands at 0.98% with Operating Profit Margin at -7.89%, Pretax Profit Margin comes in at -8.34%, and Net Profit Margin reading is -8.34%. To continue investigating profitability, this company’s Return on Assets is posted at -0.58, Equity is -0.65 and Total Capital is -0.63. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Zentalis Pharmaceuticals Inc’s Current Ratio is 6.94. Further, the Quick Ratio stands at 6.94, while the Cash Ratio is 0.85. Considering the valuation of this stock, the price to sales ratio is 3.43, the price to book ratio is 0.31.
Transactions by insiders
Recent insider trading involved Myers Scott Dunseth, Director, that happened on Apr 30 ’25 when 21000.0 shares were purchased. Chief Medical Officer, Bruns Ingmar completed a deal on Feb 06 ’25 to buy 20000.0 shares. Meanwhile, Former Director Cam Gallagher bought 687.0 shares on Feb 11 ’25.
